Intelgenx Technologies CorpTSX:IGXView on OTCQB
- LAST PRICE0.2050
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.1900/ 12
- Ask / Lots0.2300/ 5
- Open / Previous Close0.0000 / 0.2050
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IGX |
|---|---|---|
| 10:19 ET | 500 | 0.22 |
| 11:27 ET | 4000 | 0.23 |
| 12:56 ET | 500 | 0.22 |
| 01:03 ET | 3500 | 0.205 |
| 01:06 ET | 2500 | 0.205 |
| 01:08 ET | 3000 | 0.205 |
| 01:10 ET | 2500 | 0.205 |
| 01:12 ET | 7500 | 0.205 |
| 01:14 ET | 4500 | 0.205 |
| 03:00 ET | 500 | 0.215 |
| 03:39 ET | 500 | 0.205 |
Apr 8, 2024
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm(R) in Phase 2 'MONTPARK' Clinical Trial, from 7:45AM ET on Monday Apr 08, 2024 by Dow Jones
7:45AM ET on Monday Apr 08, 2024 by Dow Jones
Apr 5, 2024
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA, from 7:45AM ET on Friday Apr 05, 2024 by Dow Jones
7:45AM ET on Friday Apr 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Intelgenx Technologies Corp | 35.8M | -2.6x | --- |
Eastwood Bio-Medical Canada Inc | 60.6M | -114.1x | --- |
Pharmacielo Ltd | 28.8M | -2.1x | --- |
Red Light Holland Corp | 21.8M | -3.8x | --- |
Mountain Valley MD Holdings Inc | 19.8M | -2.7x | --- |
Nass Valley Gateway Ltd | 18.7M | -10.8x | --- |
Company Information
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.
Contact Information
- Headquarters
- 6420 Abrams StSAINT-LAURENT, QC, Canada H4S 1Y2
- Phone
- 514-331-7440
- Fax
- 514-331-7440
Executives
- Chairman of the Board
- Horst Zerbe
- President, Chief Financial Officer
- Andre Godin
- Chief Executive Officer
- Dwight Gorham
- Vice President - Intellectual Property and Legal Affairs, General Counsel of IntelGenx Corp
- Tommy Kenny
- Senior Vice President, Head of Corporate Development and Strategic Alliances of IntelGenx Corp
- David Kideckel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.8M |
|---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 174.7M |
Intelgenx Technologies Corp does not pay a dividend. | |
Beta | 3.11 |
EPS | $-0.08 |
Book Value | $-0.10 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | 25.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -802.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
